Literature DB >> 17186185

[Cenesthesia as a rare differential diagnosis of persistent idiopathic facial pain].

J Steiner1, B Bogerts, D Hoffmeyer, M Brinkers.   

Abstract

Cenesthesia is portrayed as a rare differential diagnosis to persistent idiopathic facial pain, including the resulting therapy with antipsychotics. In this case report a female patient developed persistent facial pain 2 years after manifestation of a depressive disorder. The symptoms appeared as a bizarre pain phenomenon closely resembling the psychotic phenomenon of cenesthesia (body hallucinations). Treatment with imipramine and doxepin or a combination of venlafaxin, carbamazepine, and tilidine N had not been successful. Based on diagnostic classification of the complaint as cenesthesia in the context of a depressive disorder, add-on therapy of the atypical antipsychotic ziprasidone was administered. This led to clear improvements in mood and pain symptoms after 4 weeks of treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17186185     DOI: 10.1007/s00115-006-2234-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  13 in total

1.  Olanzapine as an abortive agent for cluster headache.

Authors:  T D Rozen
Journal:  Headache       Date:  2001-09       Impact factor: 5.887

2.  Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.

Authors:  A W Schmidt; L A Lebel; H R Howard; S H Zorn
Journal:  Eur J Pharmacol       Date:  2001-08-17       Impact factor: 4.432

3.  Olanzapine in the treatment of refractory migraine and chronic daily headache.

Authors:  Stephen D Silberstein; Mario F P Peres; Mary M Hopkins; Aaron L Shechter; William B Young; Todd D Rozen
Journal:  Headache       Date:  2002-06       Impact factor: 5.887

4.  Atypical facial pain--application of the IHS criteria in a clinical sample.

Authors:  V Pfaffenrath; M Rath; W Pöllmann; W Keeser
Journal:  Cephalalgia       Date:  1993-04       Impact factor: 6.292

5.  Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial.

Authors:  Heli Forssell; Tiina Tasmuth; Olli Tenovuo; Göran Hampf; Eija Kalso
Journal:  J Orofac Pain       Date:  2004

Review 6.  [Therapy and prophylaxis of facial neuralgias and other forms of facial pain syndromes -- revised recommendations of the German Society of Migraine and Headache].

Authors:  W Paulus; S Evers; A May; U Steude; A Wolowski; V Pfaffenrath
Journal:  Schmerz       Date:  2003-01       Impact factor: 1.107

7.  [Coenesthesia--an important differential diagnosis in chronic pain syndromes].

Authors:  O Rommel; M Bokeloh; J P Malin; P Bräunig; M Strumpf; M Zenz
Journal:  Schmerz       Date:  1999-06-11       Impact factor: 1.107

8.  [Chronic pain treatment with antidepressants--metaanalysis].

Authors:  T J Feuerstein
Journal:  Schmerz       Date:  1997-06-13       Impact factor: 1.107

9.  Report of three case studies with olanzapine for chronic pain.

Authors:  Eugene D Gorski; Kerry C Willis
Journal:  J Pain       Date:  2003-04       Impact factor: 5.820

10.  Altered dopamine D2 receptor binding in atypical facial pain.

Authors:  Nora Hagelberg; Heli Forssell; Sargo Aalto; Juha O Rinne; Harry Scheinin; Tero Taiminen; Kjell Någren; Olli Eskola; Satu K Jääskeläinen
Journal:  Pain       Date:  2003-11       Impact factor: 6.961

View more
  1 in total

1.  [Pain therapy in patients with schizoaffective disorder and cancer].

Authors:  M Brinkers; G Pfau; A Voigt; C Schneemilch
Journal:  Schmerz       Date:  2015-04       Impact factor: 1.107

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.